✦ LIBER ✦

7018 Alpha-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer

✍ Scribed by Nilsson, S.; Franzen, L.; Parker, C.; Bolstad, B.; Ramdahl, T.; Thuresson, M.; Bruland, O.

Book ID: 122347268
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 50 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71396-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two-Year Survival Follow-Up of the Rando

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

✍ Nilsson, Sten; Franzén, Lars; Parker, Christopher; Tyrrell, Christopher; Blom, R 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 394 KB

714 PAIN AND QUALITY OF LIFE (QOL) ANALY

714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES

✍ Tomblyn, Michael; Nilsson, Sten; Vogelzang, Nicholas; Sartor, A. Oliver; Cislo, 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

7008 POSTER DISCUSSION Twenty-four-month

7008 POSTER DISCUSSION Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases

✍ Nilsson, S.; Haugen, I.; Aksnes, A.; O'Bryan-Tear, C.G.; Parker, C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB